Business Wire

Kyocera Develops AI-powered 5G Virtualized Base Station for the Telecommunication Infrastructure Market

18.2.2025 06:00:00 CET | Business Wire | Press release

Share

Innovative solution for next-generation networks revolutionizes connectivity, increases fronthaul coverage

Kyocera Corporation (President: Hideo Tanimoto) (TOKYO:6971) today announced that it has officially begun the full-scale development of an AI-powered 5G virtualized base station, with plans to commercialize the technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217514858/en/

System Concept (Graphic: Business Wire)

As digital transformation (DX) accelerates globally, 5G mobile networks have become a critical societal infrastructure. Kyocera is leveraging its proprietary, globally developed telecommunications and virtualization technologies to bring base station functionality to general-purpose servers using the NVIDIA GH200 Grace HopperTM Superchip. Using AI, Kyocera’s 5G virtualized base stations will enhance performance, reduce power consumption, and streamline both operations and maintenance. By offering these 5G virtualized base stations as an optimized solution to customers worldwide, Kyocera will support the advancement of 5G systems and help create a prosperous and connected society.

Features of Kyocera’s 5G Virtualized Base Station

1. AI-Powered Base Station Functionality
Using AI, the system dynamically manages traffic congestion and optimizes frequency allocation, enabling higher upload/download speeds and improved quality. AI also monitors traffic to optimize base station power consumption, enhancing energy efficiency. Additionally, AI automates and optimizes various settings needed for operation and maintenance, allowing more efficient network management.

2. Dual Connectivity Functionality
Leveraging its advanced antenna technology, Kyocera has developed O-RAN-compliant CU/DU/RU (O-CU/O-DU/O-RU) capable of handling two distinct frequency bands: Sub-6-GHz and millimeter-wave. The system can accommodate rapid traffic increases by controlling traffic data from both frequency bands on a general-purpose accelerated computing server. Future next-generation frequency bands are supported through software upgrades.

3. Base Station Sharing Functionality
Kyocera’s innovation allows multiple telecommunications operators to share a single base station (CU/DU or O-RU) to process communication data. This functionality reduces the number of base stations required, minimizing operators' capital expenditures and electricity costs, while contributing to more efficient expansion of 5G wireless network coverage.

4. Extended Coverage Area and Reduced Power Consumption
With Kyocera’s expertise in software implementation, the system can extend fronthaul distance to more than 40 kilometers, enabling broader coverage areas. Additionally, consolidating CU/DU functions on a single server reduces power consumption.

About Kyocera’s Participation in MWC 2025

Kyocera will showcase its 5G virtualized base station at Mobile World Congress 2025 (MWC), the world’s largest communications technology convention, in Barcelona, Spain, March 3-6, 2025.

Dates

March 3-6, 2025

Official Website

https://www.mwcbarcelona.com/

Venue

Fira Gran Via, Barcelona, Spain

Kyocera Booth

Hall 5, 5E12

Explanation of Terms

  1. RAN (Radio Access Network): A wireless communications network using radio waves.
  2. CU (Central Unit): A component of the wireless access network that manages data processing and control functions near the core network in a centralized manner.
  3. DU (Distributed Unit): A component within the wireless access network alongside the CU to handle wireless signal processing and functions that require real-time operation.
  4. RU (Radio Unit): A part of the wireless access network that sends and receives wireless signals, directly connecting to antennas and serving as the physical interface for wireless communication.
  5. O-RU (Open Radio Unit): An RU that complies with O-RAN standards, enabling interoperability between equipment and software from different vendors.
  6. O-RAN Alliance: An international organization that promotes the open and intelligent evolution of Radio Access Networks (RAN) through the participation of telecom operators, equipment manufacturers, and software developers. It aims to improve interoperability, flexibility, and the efficient deployment of 5G and next-generation networks.
  7. O-RAN Specifications: Common specifications developed by the O-RAN Alliance to promote the openness and interoperability of Radio Access Networks (RAN). By adhering to these specifications, companies enable flexible and efficient collaboration between devices from different manufacturers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250217514858/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye